Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (April 2024)
22 slides from Nyrada's investor presentation, Apr 18, 2024
Slide 1: Investor Presentation April 2024
Nyrada Inc. For personal use only Investor Presentation April 2024 Improving Lives, Offering Hope ASX:NYR NYRADA INC (ASX:NYR) 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should Although the Company believes that the expectations reflected in the forward-looking For personal use only not be considered as an offer or invitation to subscribe for, or purchase any s
Slide 3: About Nyrada
About Nyrada For personal use only › Nyrada is a US incorporated, Australia based drug discovery and development company specialising in novel small molecule therapeutics. › Commercially focused business model and expert team. › Experienced Board of Directors and Scientific Advisory Board with impre
Slide 4: Management Team with Proven Industry Experience
Management Team with Proven Industry Experience For personal use only Supported by specialist advisers: • Prof Gary Housley Brain injury program • Prof Junichi Nabekura Brain injury program • Dr Jim Palmer Medicinal Chemist James Bonnar - CEO Cameron Jones - CFO Dr Benny Evison - CSO • Dr Mike Bicke
Slide 5: High Calibre and Internationally Experienced Governing Board
High Calibre and Internationally Experienced Governing Board For personal use only › Nyrada operates under the direction of a governing board of international calibre › Strong track record in John Moore Dr Ian Dixon Dr Gisela Mautner Non-Executive Chair Non-Executive Director Non-Executive Director
Slide 6: Nyrada Investment Proposition
Nyrada Investment Proposition For personal use only › Globally experienced and proven team. › First-in-class therapy with novel mode of action. › Significant target market and unmet clinical demand. › Collaborations with world leading institutions, Walter Reed Army Institute of Research (WRAIR) and
Slide 7: March 2024 Capital Raise
March 2024 Capital Raise Nyrada has concluded a placement for A$1,755,000 before costs For personal use only • A placement of approximately A$1.755M of new equity capital, comprising 23,400,000 Chess New Depositary Interests (CDIs), to professional and sophisticated investors. Capital • The Placemen
Slide 8: Key 3QFY2024 Financials
Key 3QFY2024 Financials For personal use only • A$5.60 million cash at 31 March 2024 • A$4.65 million cash at 31 December 2023 • 3QFY2024 cash operating outflows – A$0.73 million • 2QFY2024 cash operating outflows – A$1.21 million • Fully subscribed placement raised A$1.76 million (before costs) • A
Slide 9: Nyrada's Lead Brain Injury Candidate – NYR-BI03
Nyrada’s Lead Brain Injury Candidate – NYR-BI03 For personal use only First-in-Class with Novel Significant Unmet Clinical Mechanism of Action Need and Market Opportunity › NYR-BI03 is a first-in-class therapy. › Targeting multiple indications. › Novel mechanism of action. › Stroke and TBI are leadi
Slide 10: Statistically Significant Neuroprotection Achieved
Statistically Significant Neuroprotection Achieved Recent preclinical study demonstrated strong efficacy and good tolerability For personal use only 42% 41% Preclinical Study Design of brain injury in penumbra region mean level of biomarkers for NYR-BI03 • The study involved inducing a focal rescued
Slide 11: Large Market Opportunity – Stroke
Large Market Opportunity – Stroke For personal use only Globally: ~15 million ~5 million people suffer left permanently strokes annually1 disabled1 One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator). Effective treatment will improve patient outcomes
Slide 12: Large Market Opportunity – Traumatic Brain Injury (TBI)
Large Market Opportunity – Traumatic Brain Injury (TBI) For personal use only Globally: ~5.5 million ~55 million people suffer severe living with effects of TBA annually3 medically treated TBI3 No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs
Slide 13: Brain Injury Trajectory, Patient Outcomes, Treatment Aims
Brain Injury Trajectory, Patient Outcomes, Treatment Aims Serial reconstruction from MRI Primary Secondary Disability Injury For personal use only Injury Level 30 mins BECAME STAYED DIED WORSE THE SAME 72 hours IMPROVED Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyr
Slide 14: Proof-of-Concept: TRPC 3/6/7 Knockout Mouse Model
Proof-of-Concept: TRPC 3/6/7 Knockout Mouse Model Middle cerebral artery occlusion (MCAO) stroke model shows neuroprotection in TRPC3,6,7 triple knockout mouse For personal use only › TRPC 3/6/7 KO mice have significantly smaller lesion size compared to WT in a mouse middle cerebral artery occlusion
Slide 15: TRPC 3/6/7 Ion Channels as a Therapeutic Target
TRPC 3/6/7 Ion Channels as a Therapeutic Target › Glutamate release following brain injury results in calcium entry via TRPC ion channels For personal use only › Excessive calcium build-up leads to neuronal cell death › Blocking TRPC 3/6/7 ion channels is neuroprotective against secondary brain inju
Slide 16: Brain Injury Program Milestones Ahead
Brain Injury Program Milestones Ahead For personal use only 1H CY2024 2H CY2024 CY2025 and beyond CY 2025 › Phase I clinical trial for NYR- › Investigational New Drug application BI03 expected to commence. with the FDA Q1CY2024 › Data from the GLP studies and › Good Laboratory Practice (GLP) Phase I
Slide 17: Brain Injury Program - Indicative Phase I Study Design
Brain Injury Program - Indicative Phase I Study Design Commencing in 2HCY2024 OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 For personal use only DESIGN • Randomised, double-blind placebo – PARTICIPANTS controlled, dose escalation design • Male and female healthy vo
Slide 18: Summary
Summary Nyrada is advancing a novel drug candidate to reduce the secondary For personal use only brain injury caused by stroke or traumatic brain injury. Strong First-in-class Large Near term efficacy therapy patient markets milestones NYR-BI03 protects the With a novel Significant market Final safe
Slide 19: Nyrada's Vision and Strategy
Nyrada’s Vision and Strategy For personal use only Our vision To become a high growth pharmaceutical discovery and development company specialising in early-stage drug development of novel treatments. Our strategy To develop treatments for diseases where there is an unmet clinical need, or where cur
Slide 20: Commercially Focused Business Model
Commercially Focused Business Model We aim to create value for patients and shareholders by advancing highly optimised drug For personal use only candidates towards out-licensing. Lean, scalable Experienced Large molecule Attractive Highly capable team operating governing and library operating with
Slide 21: References
References 1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular- accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20is%20high%20blood%20pressure For personal use only 2 – Databridge Market Research - https://www.databridgemark
Slide 22: Brain Injury Solution Animation
For personal use only Brain Injury Solution Animation Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 22